Comparison
Abaloparatid vs. Enfuvirtid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
247062-33-5
159519-65-0
Molecular weight
3960.6 g/mol
4491.88 g/mol
Half-life
1.7 h
no data
Sequence
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2no data
Mechanism of action
Abaloparatid
Abaloparatide is a synthetic analogue of the first 34 amino acids of parathyroid hormone-related protein (PTHrP). Like parathyroid hormone and teriparatide it binds the PTH-1 receptor, but the literature describes it as preferentially engaging the so-called RG conformation of the receptor, which is associated with shorter signaling duration. As for the entire drug class, intermittent receptor activation is regarded as the mechanistic basis for the stimulation of bone-forming osteoblasts observed in studies, whereas continuously elevated exposure would tend to favor bone resorption. From this binding behavior the literature derives a discussed balance between bone formation and bone resorption.
Enfuvirtid
Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
4
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Abaloparatid and Enfuvirtid?
- Abaloparatid is classified as "Research other", while Enfuvirtid is classified as "Research other". Abaloparatid: Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile. Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Abaloparatid or Enfuvirtid?
- The highest available evidence level is "Human RCT" for Abaloparatid and "Human RCT" for Enfuvirtid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Abaloparatid and Enfuvirtid in Germany and the United States?
- Germany: Abaloparatid — Prescription, Enfuvirtid — Prescription. United States: Abaloparatid — Prescription, Enfuvirtid — Prescription. These are factual summaries with source and review date on the individual pages.